396 results
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
), the “at will” nature of your employment may only be changed in an express written agreement signed by you and an authorized executive officer
8-K
EX-10.2
ORKA
Oruka Therapeutics Inc.
4 Oct 24
Departure of Directors or Certain Officers
4:05pm
(subject to the terms of this Agreement), the “at will” nature of your employment may only be changed in an express written agreement signed by you
8-K
EX-10.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
-looking statements” disclaimer or any other statements that are similarly predictive or forward-looking in nature, in each case, other than any … the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would
8-K
EX-99.2
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
The accompanying notes are an integral part of this financial statement.
ORUKA THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENT
1. Nature of the Business
8-K
EX-99.4
fvs5u2vlc9
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-10.10
isv0 ragce6b35z
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-3.6
up8y9hpb9emkr 44xi2
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.3
b7yd7xu30m9zbzw360
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-14.1
bv7if 12rg1brhi31d
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
EX-99.1
ddpt g6nshg8ev
26 Aug 24
Business combination disclosure
7:53pm
425
aefeqb1zl 220x16fw8
26 Aug 24
Business combination disclosure
7:53pm
8-K
8yqz2
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
y2xcwqaw
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
kn5ugg
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
8-K
a39aydjgx4wful ou
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
phz i3qla2mq
16 Aug 24
Business combination disclosure
4:27pm
425
EX-99.1
lth6d2spr6ufk1wdwa7
16 Aug 24
Business combination disclosure
4:27pm
8-K
5lngmrso2g00ukms3
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm
8-K
EX-99.1
9g496bgjlo
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm